Amphastar Pharmaceuticals Inc.

45.89+1.02+2.27%Vol 351.35K1Y Perf 57.22%
Oct 4th, 2023 16:00 DELAYED
BID45.96 ASK47.99
Open44.89 Previous Close44.87
Pre-Market- After-Market45.96
 - -  0.07 0.15%
Target Price
38.00 
Analyst Rating
Strong Buy 1.50
Potential %
-17.19 
Finscreener Ranking
★★★+     51.47
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     55.51
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.25
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
46.77 
Earnings Rating
Strong Buy
Market Cap2.24B 
Earnings Date
6th Nov 2023
Alpha0.01 Standard Deviation0.12
Beta0.87 

Today's Price Range

44.0846.21

52W Range

26.7667.66

5 Year PE Ratio Range

-139.30921.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.51%
1 Month
-17.72%
3 Months
-22.14%
6 Months
15.82%
1 Year
57.22%
3 Years
136.16%
5 Years
135.04%
10 Years
-

TickerPriceChg.Chg.%
AMPH45.891.02002.27
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.80
0.16
0.20
68.70
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
48.30
21.30
27.10
8.00
15.79
RevenueValueIndustryS&P 500US Markets
363.96M
7.53
11.44
12.28
Earnings HistoryEstimateReportedSurprise %
Q02 20230.520.5811.54
Q01 20230.400.5230.00
Q04 20220.340.6797.06
Q03 20220.320.320.00
Q02 20220.300.3310.00
Q01 20220.330.4742.42
Q04 20210.380.4210.53
Q03 20210.220.46109.09
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.676.35Positive
12/2023 QR0.7214.29Positive
12/2023 FY2.507.30Positive
12/2024 FY3.2521.72Positive
Next Report Date6th Nov 2023
Estimated EPS Next Report0.67
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume351.35K
Shares Outstanding48.86K
Shares Float34.98M
Trades Count8.05K
Dollar Volume16.08M
Avg. Volume480.93K
Avg. Weekly Volume398.80K
Avg. Monthly Volume608.71K
Avg. Quarterly Volume435.29K

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock closed at 44.87 per share at the end of the most recent trading day (a -1.9% change compared to the prior day closing price) with a volume of 413.32K shares and market capitalization of 2.24B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2027 people. Amphastar Pharmaceuticals Inc. CEO is Jack Yongfeng Zhang.

The one-year performance of Amphastar Pharmaceuticals Inc. stock is 57.22%, while year-to-date (YTD) performance is 60.14%. AMPH stock has a five-year performance of 135.04%. Its 52-week range is between 26.76 and 67.66, which gives AMPH stock a 52-week price range ratio of 46.77%

Amphastar Pharmaceuticals Inc. currently has a PE ratio of 19.20, a price-to-book (PB) ratio of 2.76, a price-to-sale (PS) ratio of 3.72, a price to cashflow ratio of 13.10, a PEG ratio of -, a ROA of 12.08%, a ROC of 13.57% and a ROE of 17.76%. The company’s profit margin is 15.79%, its EBITDA margin is 27.10%, and its revenue ttm is $363.96 Million , which makes it $7.53 revenue per share.

Of the last four earnings reports from Amphastar Pharmaceuticals Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.67 for the next earnings report. Amphastar Pharmaceuticals Inc.’s next earnings report date is 06th Nov 2023.

The consensus rating of Wall Street analysts for Amphastar Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $38, which is -17.19% compared to the current price. The earnings rating for Amphastar Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amphastar Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amphastar Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.49, ATR14 : 1.72, CCI20 : -96.33, Chaikin Money Flow : -0.34, MACD : -2.01, Money Flow Index : 41.04, ROC : -1.97, RSI : 34.34, STOCH (14,3) : 25.38, STOCH RSI : 0.17, UO : 46.40, Williams %R : -74.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amphastar Pharmaceuticals Inc. in the last 12-months were: Deflin Gayle (Sold 6 019 shares of value $263 606 ), Floyd F. Petersen (Sold 2 491 shares of value $81 472 ), Jacob Liawatidewi (Option Excercise at a value of $333 674), Jacob Liawatidewi (Sold 16 494 shares of value $677 748 ), Lee Howard (Option Excercise at a value of $278 373), Lee Howard (Option Exercise at a value of $278 373), Lee Howard (Sold 16 679 shares of value $750 960 ), Peters William (Option Excercise at a value of $2 471 861), Peters William (Sold 163 393 shares of value $7 707 376 ), PETERS WILLIAM J (Option Exercise at a value of $146 850), PETERS WILLIAM J (Sold 11 000 shares of value $509 859 ), Petersen Floyd (Sold 6 991 shares of value $281 665 ), Prins Richard (Sold 0 shares of value $-166 900 ), Prins Richard (Sold 16 163 shares of value $771 715 ), William J. Peters (Option Excercise at a value of $722 744), William J. Peters (Sold 68 032 shares of value $2 577 781 ), Yakob Liawatidewi (Option Excercise at a value of $761 768), Yakob Liawatidewi (Sold 45 310 shares of value $2 208 742 ), Zasloff Michael (Sold 20 259 shares of value $1 046 420 ), Zhou Rong (Sold 0 shares of value $-609 018 ), Zhou Rong (Option Exercise at a value of $72 000), Zhou Rong (Sold 20 000 shares of value $942 250 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.50

Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.

CEO: Jack Yongfeng Zhang

Telephone: +1 909 980-9484

Address: 11570 6th Street, Rancho Cucamonga 91730, CA, US

Number of employees: 2 027

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

57%43%

 

News

Stocktwits